Allogene Therapeutics, Inc. (ALLO) stock
Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%
Earnings
Allogene Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Allogene Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | – | – | -$0.15 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026during market hours | $4.64M | – | -$0.13 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026during market hours | – | – | -$0.18 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026during market hours | – | – | -$0.17 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | – | – | -$0.19 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025during market hours | – | – | -$0.23 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025during market hours | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 13, 2025during market hours | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024during market hours | – | – | -$0.35 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024during market hours | $22.00K | -57.7% | -$0.38 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024during market hours | $21.00K | -55.3% | -$0.51 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | $43.00K | -12.2% | -$0.37 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023during market hours | $44.00K | -48.8% | -$0.53 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023during market hours | $52.00K | -14.8% | -$0.68 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023during market hours | $47.00K | -7.8% | -$0.66 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022during market hours | $49.00K | 0.0% | -$0.58 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022during market hours | $86.00K | – | -$0.52 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $61.00K | – | -$0.56 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022during market hours | $51.00K | – | -$0.54 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021during market hours | $49.00K | – | -$0.57 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Allogene Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| GAAP Operating ExpensesGAAP | FY2026 | $225.00M | – | New | Aug 12, 2026 |
| operating expensenon-GAAP | FY2026 | $165.00M | – | New | Aug 12, 2026 |
| estimated non-cash stock-based compensation expense | FY2026 | $35.00M | – | Lowered | Mar 12, 2026 |
| GAAP Operating ExpensesGAAP | FY2026 | $225.00M | – | New | Nov 5, 2026 |
| GAAP Operating ExpensesGAAP | FY2026 | $225.00M | $210.00M | Raised | May 13, 2026 |
| non-cash stock-based compensation expensenon-GAAP | FY2026 | $35.00M | – | Lowered | May 13, 2026 |
| operating cash expensenon-GAAP | FY2026 | $165.00M | – | New | May 13, 2026 |
| operating cash expense | FY2026 | $150.00M | – | New | Mar 12, 2026 |
| operating expensenon-GAAP | FY2026 | $165.00M | – | New | Nov 5, 2026 |
Guidance history
Every forecast Allogene Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | GAAP Operating Expenses | FY2026 | $225.00M | New |
| Nov 5, 2026 | operating expense | FY2026 | $165.00M | New |
| Aug 12, 2026 | GAAP Operating Expenses | FY2026 | $225.00M | New |
| Aug 12, 2026 | operating expense | FY2026 | $165.00M | New |
| May 13, 2026 | GAAP Operating Expenses | FY2026 | $225.00M | Raised |
| May 13, 2026 | operating cash expense | FY2026 | $165.00M | New |
| May 13, 2026 | non-cash stock-based compensation expense | FY2026 | $35.00M | Lowered |
| Mar 12, 2026 | operating cash expense | FY2026 | $150.00M | New |
| Mar 12, 2026 | estimated non-cash stock-based compensation expense | FY2026 | $35.00M | Lowered |
| Mar 12, 2026 | GAAP Operating Expenses | FY2026 | $210.00M | New |
| Nov 6, 2025 | decrease in cash, cash equivalents, and investments | FY2025 | $150.00M | New |
| Nov 6, 2025 | GAAP Operating Expenses | FY2025 | $230.00M | New |
| Aug 13, 2025 | decrease in cash, cash equivalents, and investments | FY2025 | $150.00M | Raised |
| Aug 13, 2025 | GAAP Operating Expenses | FY2025 | $230.00M | Reaffirmed |
| May 13, 2025 | decrease in cash, cash equivalents, and investments | FY2025 | $150.00M | Raised |
| May 13, 2025 | non-cash stock-based compensation expense | FY2025 | $45.00M | Lowered |
| May 13, 2025 | GAAP Operating Expenses | FY2025 | $230.00M | New |
| Mar 13, 2025 | GAAP Operating Expenses | FY2025 | $250.00M | New |
| Mar 13, 2025 | decrease in cash, cash equivalents and investments | FY2025 | -$170.00M | New |
| Nov 7, 2024 | GAAP Operating Expenses | FY2024 | $300.00M | Reaffirmed |
| Aug 7, 2024 | decrease in cash, cash equivalents, and investments | FY2024 | $200.00M | Raised |
| Aug 7, 2024 | estimated non-cash stock-based compensation expense | FY2024 | $60.00M | Lowered |
| Aug 7, 2024 | GAAP Operating Expenses | FY2024 | $300.00M | Reaffirmed |
| May 13, 2024 | decrease in cash, cash equivalents, and investments | FY2024 | $200.00M | Raised |
| May 13, 2024 | estimated non-cash stock-based compensation expense | FY2024 | $60.00M | Lowered |
| May 13, 2024 | GAAP Operating Expenses | FY2024 | $300.00M | Raised |
| Mar 14, 2024 | decrease in cash, cash equivalents, and investments | FY2024 | $190.00M | New |
| Mar 14, 2024 | estimated non-cash stock-based compensation expense | FY2024 | $60.00M | Lowered |
| Mar 14, 2024 | GAAP Operating Expenses | FY2024 | $280.00M | New |
| Nov 2, 2023 | decrease in cash, cash equivalents, and investments | FY2023 | $230.00M | Raised |
| Nov 2, 2023 | estimated non-cash stock-based compensation expense | FY2023 | $80.00M | Lowered |
| Nov 2, 2023 | GAAP Operating Expenses | FY2023 | $340.00M | Reaffirmed |
| Aug 2, 2023 | decrease in cash, cash equivalents, and investments | FY2023 | $230.00M | Raised |
| Aug 2, 2023 | estimated non-cash stock-based compensation expense | FY2023 | $80.00M | Lowered |
| Aug 2, 2023 | GAAP Operating Expenses | FY2023 | $340.00M | Reaffirmed |
| May 3, 2023 | decrease in cash, cash equivalents, and investments | FY2023 | $230.00M | Raised |
| May 3, 2023 | estimated non-cash stock-based compensation expense | FY2023 | $80.00M | Lowered |
| May 3, 2023 | GAAP Operating Expenses | FY2023 | $340.00M | Lowered |
| Feb 28, 2023 | decrease in cash, cash equivalents, and investments | FY2023 | $250.00M | New |
| Feb 28, 2023 | estimated non-cash stock-based compensation expense | FY2023 | $90.00M | Lowered |
| Feb 28, 2023 | GAAP Operating Expenses | FY2023 | $350.00M | New |
| Aug 9, 2022 | non-cash stock-based compensation expense | FY2022 | $90.00M – $100.00M | Reaffirmed |
| Aug 9, 2022 | Cash burn | FY2022 | $250.00M | Raised |
| Aug 9, 2022 | GAAP Operating Expenses | FY2022 | $360.00M | Lowered |
| May 4, 2022 | GAAP Operating Expenses | FY2022 | $360.00M – $390.00M | Reaffirmed |
| Feb 23, 2022 | estimated non-cash stock-based compensation expense | FY2022 | $90.00M – $100.00M | New |
| Feb 23, 2022 | GAAP Operating Expenses | FY2022 | $360.00M – $390.00M | New |
| Nov 4, 2021 | GAAP Operating Expenses | FY2021 | $300.00M – $330.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Allogene Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?